SlideShare a Scribd company logo
1 of 18
Anticancer
Alkylating agents
Dr. S. Parasuraman
Faculty of Pharmacy, AIMST.
Alkylating agents
Nitrogen mustards

Ethylenimine
Alkyl sulfonate
Nitrosoureas
Triazine
Methylhyderazine

Mechlorethamine
Cyclophosphamide
Ifosfamide
Chlorambucil
Melphalan
Thio-TEPA
Busulfan
Carmustine
Lomustine
Dacarbazine
Temozolomide
Procarbazine
Alkylating agents
• Alkylating agents produce highly reactive carbonium ion
intermediates or related transition complex which
transfer alkyl group to cellular macromolecules by
covalent bonds.

• Alkylating agents cross link with carboxyl, hydroxyl,
amino,

sulfhydryl

and

phosphate

groups

of

biomacromolecules results abnormal base paring/
scission of DNA Stand.
Alkylating agents
MOA & SAR:

The chemotherapeutic
and cytotoxic effects
are directly related to
the alkylation of DNA.
The 7th nitrogen atom
of guanine is suitable
for
formation
of
covalent bond with
bifunctional alkylating
agent.
Pharmacological actions
• Cytotoxic actions:
– Interfere with DNA integrity and functions to induce cell

death in rapidly proliferating tissues.
– Lethality of DNA alkylation depends on the recognition of
the adduct, the creation of DNA stand breaks by repair

enzymes.
– In nondividing cells, DNA damage activation depends on the
presence of p53 gene. Malignant cells with mutant/ absent

p53 gene fail to suspend cell-cycle progression (don’t cause
apoptosis) and exhibit resistance to alkylating agents.
Toxicities of alkylating agents
• Bone marrow toxicity
– Causes dose-dependent toxicity to bone marrow elements
– Myelosuppression
– Suppression of cellular and humoral immunity

• Mucosal toxicity
– Highly toxic to mucosal cells and intestinal mucosa

• Neurotoxicity
– Nausea, vomiting (after I.V administration)
– Ifosfamide is the most neurotoxic agent in this class (alter
mental status, coma, generalized seizures and cerebellar ataxia)

• Other: Leukemogensis, male and female reproductive
system toxicity.
• Mechlorethamine
–
–
–
–
–

First nitrogen mustard; most reactive
Slow I.V. injection may cause sloughing
Used for Hodgkin and non-Hodgkin lymphomas
Largely replaced by cyclophosphamide and melphalan.
Dose: 0.1 mg/kg i.v. daily X 4 days (courses may be
repeated at suitable intervals)
– It is also used topically for treatment of cutaneous T-cell
lymphoma
– Toxicity: Block reproductive functions, produce menstrual
irregularities or premature ovarian failure in women and
oligospermia in men. First trimester of pregnancy and later
stage of pregnancy it should not be used.
• Cyclophosphosphamide
– Inactive as such
– Transformed to active metabolites in liver:
(aldophosphamide, phosphoramide mustard)
– Chloramphenicol retards the metabolism of
cyclophosphamide.
– It is well absorbed orally, activated by CYP2B.
– Cyclophosphamide is potent immunosuppressive agent, it
has been used to prevent organ rejection after
transplantation.
– Dose: 2-3 mg/kg/ day oral; 10-15 mg/kg i.v.
• Ifosfamide
– Analog of cyclophosphamide has a longer dose-dependent
t1/2 and it also activated by hydroxylation in the liver.
– Used in bronchogenic, breast, testicular, bladder, head and
neck carcinomas, oeseogenic sarcoma and some lymphomas.
– Approved for germ cell testicular cancer
– Produce dose limiting toxicity – haemorrhagic cystitis. Sever
urinary tract and CNS toxicity
– Toxicity can be reduced by administering mesna (-SH
compound). mesna inactivates the vasicotoxic metabolites of
ifosfamide and cyclophosphamide.
– Ifosfamide causes less alopecia and is less emetogenic than
cyclophosphamide.
– Dose: 0.1 g inj.
• Chlorambucil
– Slow acting alkylating agent
– Active against lymphoid, myeloid tissue cancers
– It is the drug of choice for the long-term maintenance
therapy for chronic lymphatic leukaemia, non-Hodgkin
lymphoma and few solid tumours.
– It has immunosuppressant property
– Dose: 4-10 mg daily for 3-6 weeks, then 2 mg/kg daily for
maintenance
• Melphalan
– The pharmacological and cytotoxic properties of
melphalan is similar to mechlorethamine. The drug is not a
vesicant
– Effective in multiple myeloma and advanced ovarian
cancer
– Toxicity: Bone marrow toxicity
– Dose: 10 mg daily for 7 days or 6 mg/ day for 2-3 weeks-----------4 weeks gap--------- 2 to 4 mg/day for maintenance
orally.
• Thio-TEPA
–
–
–
–

It is an ethylenimine
Highly toxic
Used in ovarian and bladder cancer
Dose: 0.3-0.4 mg/kg i.v. at 1-4 weeks intervels
• Busulfan
– Highly specific for myeloid elements and granulocyte
– Toxicity: hyperuricaemia is common; pulmonary fibrosis
and skin pigmentation are specific adverse effects.
– Drug of choice for chronic myeloid leukaemia
– Dose: 2-6 mg/ day, orally
• Nitrosoureas
– It is lipid soluble alkylating agents with a wide range of
antitumour activity.
– Cross BBM
– Effective in meningeal leukaemias and brain cancer
– Toxicity: Nausea, vomiting are common; CNS toxicity, bone
marrow depression (delayed effect; will take 6 weeks to
develop), visceral fibrosis and renal damage can occur
– Dose: 100-130 mg/m2 BSA single oral dose every 6 weeks.
• Dacarbazine (DTIC)
– After activation in liver, the active metabolite methylate
the DNA and interfere with its function.
– Used for malignant melanoma, Hodgkin’s disease
– Toxicity: Nausea, vomiting, flu-like symptoms, neuropathy
and myelosuppression
– Dose: 3.5 mg/kg/day i.v. for 10 days, repeated after 4
weeks
• Temozolamide
– Orally active triazine methylating agent is the drug of
choice for glioma and other malignant brain tumour.
– Also used for melanoma
– Toxicity: Nausea, vomiting, flu-like symptoms, neuropathy
and myelosuppression
– Dose: 100- 200 mg/day
• Procarbazine
– It is not classical alkylating agent, but has similar
properties.
– After metabolizing, procarbazine methylates and
depolymerizes DNA and causing chromosomal damage
and inhibit nucleic acid synthesis.
– Procarbazine is component of MOPP regimen for Hodgkin’s
and related lymphomas and alternative drug for brain
tumours.
– It is a week MAO inhibitor, produce sedation and other
CNS effects.
– Interact with food, drugs and alcohol. With alcohol,
procarbazine causes hot flushing and disulfiram-like
reaction.
– Toxicity: Vomiting, leucopenia, thrombocytopenia
– Dose: 100 mg/m2/ dayfor 14 days in 28 days cycle.
Thank you

More Related Content

What's hot

Alkylating agents and antimetabolites
Alkylating agents and antimetabolitesAlkylating agents and antimetabolites
Alkylating agents and antimetabolitesGedion Yilma
 
Antineoplastic agents
Antineoplastic agentsAntineoplastic agents
Antineoplastic agentsRobin Gulati
 
cancer chemotherapy
cancer chemotherapycancer chemotherapy
cancer chemotherapyGamitKinjal
 
Medicinal chemistry- antimalerial agents
Medicinal chemistry- antimalerial agentsMedicinal chemistry- antimalerial agents
Medicinal chemistry- antimalerial agentsDHARMENDRA BARIA
 
Antineoplastic agents-Anticancer drugs
Antineoplastic agents-Anticancer drugsAntineoplastic agents-Anticancer drugs
Antineoplastic agents-Anticancer drugskencha swathi
 
Chapter 20 alkylating agent extra
Chapter 20  alkylating agent extraChapter 20  alkylating agent extra
Chapter 20 alkylating agent extraNilesh Kucha
 
2. alkylating & anti-metabolite drugs
2. alkylating  &  anti-metabolite drugs2. alkylating  &  anti-metabolite drugs
2. alkylating & anti-metabolite drugsHarshikaPatel6
 
cancer chemotherapy
cancer chemotherapycancer chemotherapy
cancer chemotherapyNaser Tadvi
 
medicinal chemistry of Anticancer agents
medicinal chemistry of Anticancer agentsmedicinal chemistry of Anticancer agents
medicinal chemistry of Anticancer agentsGanesh Mote
 
Antihyperlipidemic drugs
Antihyperlipidemic drugsAntihyperlipidemic drugs
Antihyperlipidemic drugsLikhita Kolli
 
Gastric Proton pump inhibitors
Gastric Proton pump inhibitorsGastric Proton pump inhibitors
Gastric Proton pump inhibitorskencha swathi
 
Classification of anti cancer drugs
Classification of anti cancer drugs Classification of anti cancer drugs
Classification of anti cancer drugs pgclubrcc
 
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRY
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRYORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRY
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRYSaurabh Badole
 
Medicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agentsMedicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agentsDHARMENDRA BARIA
 
Sulphonamides (Sulfonamides) and Sulfones || B.Pharm VI Semester || Medicinal...
Sulphonamides (Sulfonamides) and Sulfones || B.Pharm VI Semester || Medicinal...Sulphonamides (Sulfonamides) and Sulfones || B.Pharm VI Semester || Medicinal...
Sulphonamides (Sulfonamides) and Sulfones || B.Pharm VI Semester || Medicinal...Mr.S.SEETARAM SWAMY
 
ANTI CANCER DRUGS[ANTI-NEOPLASTIC DRUGS] MEDICINAL CHEMISTRY BY P. RAVISANKAR.
ANTI CANCER DRUGS[ANTI-NEOPLASTIC DRUGS] MEDICINAL CHEMISTRY BY P. RAVISANKAR.ANTI CANCER DRUGS[ANTI-NEOPLASTIC DRUGS] MEDICINAL CHEMISTRY BY P. RAVISANKAR.
ANTI CANCER DRUGS[ANTI-NEOPLASTIC DRUGS] MEDICINAL CHEMISTRY BY P. RAVISANKAR.Dr. Ravi Sankar
 

What's hot (20)

Alkylating agents and antimetabolites
Alkylating agents and antimetabolitesAlkylating agents and antimetabolites
Alkylating agents and antimetabolites
 
Antineoplastic agents
Antineoplastic agentsAntineoplastic agents
Antineoplastic agents
 
cancer chemotherapy
cancer chemotherapycancer chemotherapy
cancer chemotherapy
 
Medicinal chemistry- antimalerial agents
Medicinal chemistry- antimalerial agentsMedicinal chemistry- antimalerial agents
Medicinal chemistry- antimalerial agents
 
Antineoplastic agents-Anticancer drugs
Antineoplastic agents-Anticancer drugsAntineoplastic agents-Anticancer drugs
Antineoplastic agents-Anticancer drugs
 
Basic principles of chemotherapy
Basic principles of chemotherapyBasic principles of chemotherapy
Basic principles of chemotherapy
 
Chapter 20 alkylating agent extra
Chapter 20  alkylating agent extraChapter 20  alkylating agent extra
Chapter 20 alkylating agent extra
 
2. alkylating & anti-metabolite drugs
2. alkylating  &  anti-metabolite drugs2. alkylating  &  anti-metabolite drugs
2. alkylating & anti-metabolite drugs
 
Anti Cancer Drugs
Anti  Cancer DrugsAnti  Cancer Drugs
Anti Cancer Drugs
 
Cancer chemotherapy
Cancer  chemotherapyCancer  chemotherapy
Cancer chemotherapy
 
cancer chemotherapy
cancer chemotherapycancer chemotherapy
cancer chemotherapy
 
medicinal chemistry of Anticancer agents
medicinal chemistry of Anticancer agentsmedicinal chemistry of Anticancer agents
medicinal chemistry of Anticancer agents
 
Antihyperlipidemic drugs
Antihyperlipidemic drugsAntihyperlipidemic drugs
Antihyperlipidemic drugs
 
Gastric Proton pump inhibitors
Gastric Proton pump inhibitorsGastric Proton pump inhibitors
Gastric Proton pump inhibitors
 
Classification of anti cancer drugs
Classification of anti cancer drugs Classification of anti cancer drugs
Classification of anti cancer drugs
 
Anti Amoebic Drugs
Anti Amoebic DrugsAnti Amoebic Drugs
Anti Amoebic Drugs
 
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRY
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRYORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRY
ORAL HYPOGLYCEMIC AGENTS MEDICINAL CHEMISTRY
 
Medicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agentsMedicinal chemistry-Anticancer agents
Medicinal chemistry-Anticancer agents
 
Sulphonamides (Sulfonamides) and Sulfones || B.Pharm VI Semester || Medicinal...
Sulphonamides (Sulfonamides) and Sulfones || B.Pharm VI Semester || Medicinal...Sulphonamides (Sulfonamides) and Sulfones || B.Pharm VI Semester || Medicinal...
Sulphonamides (Sulfonamides) and Sulfones || B.Pharm VI Semester || Medicinal...
 
ANTI CANCER DRUGS[ANTI-NEOPLASTIC DRUGS] MEDICINAL CHEMISTRY BY P. RAVISANKAR.
ANTI CANCER DRUGS[ANTI-NEOPLASTIC DRUGS] MEDICINAL CHEMISTRY BY P. RAVISANKAR.ANTI CANCER DRUGS[ANTI-NEOPLASTIC DRUGS] MEDICINAL CHEMISTRY BY P. RAVISANKAR.
ANTI CANCER DRUGS[ANTI-NEOPLASTIC DRUGS] MEDICINAL CHEMISTRY BY P. RAVISANKAR.
 

Similar to Anticancer drugs 2 alkylating agents

Similar to Anticancer drugs 2 alkylating agents (20)

ALKYLATING AGENT. antineoplastic agentspptx
ALKYLATING AGENT. antineoplastic agentspptxALKYLATING AGENT. antineoplastic agentspptx
ALKYLATING AGENT. antineoplastic agentspptx
 
ALKYLATING-AGENTS-1-NEW.pdf
ALKYLATING-AGENTS-1-NEW.pdfALKYLATING-AGENTS-1-NEW.pdf
ALKYLATING-AGENTS-1-NEW.pdf
 
Anticancer drugs1
Anticancer drugs1Anticancer drugs1
Anticancer drugs1
 
Alkylating agents -Medicinal Chemistry
Alkylating agents -Medicinal Chemistry Alkylating agents -Medicinal Chemistry
Alkylating agents -Medicinal Chemistry
 
Chemotherapeutic agents
Chemotherapeutic agents Chemotherapeutic agents
Chemotherapeutic agents
 
Chemotherapeutic agents in ENT
Chemotherapeutic agents in ENTChemotherapeutic agents in ENT
Chemotherapeutic agents in ENT
 
Antituberculosis drugs
Antituberculosis drugsAntituberculosis drugs
Antituberculosis drugs
 
Chemotherapy in Breast Cancer
Chemotherapy in Breast CancerChemotherapy in Breast Cancer
Chemotherapy in Breast Cancer
 
Anti tuberculin drugs [autosaved]
Anti tuberculin drugs [autosaved]Anti tuberculin drugs [autosaved]
Anti tuberculin drugs [autosaved]
 
Anticancer drugs
Anticancer drugsAnticancer drugs
Anticancer drugs
 
Chemotherapy drugs in gynecological oncology
Chemotherapy drugs in gynecological oncologyChemotherapy drugs in gynecological oncology
Chemotherapy drugs in gynecological oncology
 
Neoplasm and Antineoplastic Agents
Neoplasm and Antineoplastic AgentsNeoplasm and Antineoplastic Agents
Neoplasm and Antineoplastic Agents
 
Dapsone, colchicine
Dapsone, colchicineDapsone, colchicine
Dapsone, colchicine
 
Antituberculosis drugs converted
Antituberculosis drugs convertedAntituberculosis drugs converted
Antituberculosis drugs converted
 
Anticancer compounds.ppt
Anticancer compounds.pptAnticancer compounds.ppt
Anticancer compounds.ppt
 
CHEMOTHERAPY IN ENT
CHEMOTHERAPY IN ENTCHEMOTHERAPY IN ENT
CHEMOTHERAPY IN ENT
 
chemotheraphy in ent.pdf
chemotheraphy in ent.pdfchemotheraphy in ent.pdf
chemotheraphy in ent.pdf
 
Cytotoxic Drug.pptx
Cytotoxic Drug.pptxCytotoxic Drug.pptx
Cytotoxic Drug.pptx
 
Anti neoplastic agents
Anti neoplastic agentsAnti neoplastic agents
Anti neoplastic agents
 
Anthelmintic
AnthelminticAnthelmintic
Anthelmintic
 

More from Subramani Parasuraman

Role of preclinical studies in drug discovery
Role of preclinical studies in drug discoveryRole of preclinical studies in drug discovery
Role of preclinical studies in drug discoverySubramani Parasuraman
 
Tolerance, autoimmunity and autoimmune diseases.pptx
Tolerance, autoimmunity and autoimmune diseases.pptxTolerance, autoimmunity and autoimmune diseases.pptx
Tolerance, autoimmunity and autoimmune diseases.pptxSubramani Parasuraman
 
Introduction to pharmacology (For Allied health students)
Introduction to pharmacology (For Allied health students)Introduction to pharmacology (For Allied health students)
Introduction to pharmacology (For Allied health students)Subramani Parasuraman
 
Pharmacodynamics - Introduction (Allied health students)
Pharmacodynamics - Introduction (Allied health students)Pharmacodynamics - Introduction (Allied health students)
Pharmacodynamics - Introduction (Allied health students)Subramani Parasuraman
 
Sustainability in preclinical drug discovery.pptx
Sustainability in preclinical drug discovery.pptxSustainability in preclinical drug discovery.pptx
Sustainability in preclinical drug discovery.pptxSubramani Parasuraman
 
Role of preclinical studies in drug discovery.pptx
Role of preclinical studies in drug discovery.pptxRole of preclinical studies in drug discovery.pptx
Role of preclinical studies in drug discovery.pptxSubramani Parasuraman
 
Research with animals and animal models.pptx
Research with animals and animal models.pptxResearch with animals and animal models.pptx
Research with animals and animal models.pptxSubramani Parasuraman
 
Cerebellum and control of postures and movements.pptx
Cerebellum and control of postures and movements.pptxCerebellum and control of postures and movements.pptx
Cerebellum and control of postures and movements.pptxSubramani Parasuraman
 
Drugs used in haematological disorders
Drugs used in haematological disordersDrugs used in haematological disorders
Drugs used in haematological disordersSubramani Parasuraman
 

More from Subramani Parasuraman (20)

Role of preclinical studies in drug discovery
Role of preclinical studies in drug discoveryRole of preclinical studies in drug discovery
Role of preclinical studies in drug discovery
 
Tolerance, autoimmunity and autoimmune diseases.pptx
Tolerance, autoimmunity and autoimmune diseases.pptxTolerance, autoimmunity and autoimmune diseases.pptx
Tolerance, autoimmunity and autoimmune diseases.pptx
 
Introduction to pharmacology (For Allied health students)
Introduction to pharmacology (For Allied health students)Introduction to pharmacology (For Allied health students)
Introduction to pharmacology (For Allied health students)
 
Pharmacodynamics - Introduction (Allied health students)
Pharmacodynamics - Introduction (Allied health students)Pharmacodynamics - Introduction (Allied health students)
Pharmacodynamics - Introduction (Allied health students)
 
Sustainability in preclinical drug discovery.pptx
Sustainability in preclinical drug discovery.pptxSustainability in preclinical drug discovery.pptx
Sustainability in preclinical drug discovery.pptx
 
Role of preclinical studies in drug discovery.pptx
Role of preclinical studies in drug discovery.pptxRole of preclinical studies in drug discovery.pptx
Role of preclinical studies in drug discovery.pptx
 
Research with animals and animal models.pptx
Research with animals and animal models.pptxResearch with animals and animal models.pptx
Research with animals and animal models.pptx
 
Nicotine and Tobacco
Nicotine and TobaccoNicotine and Tobacco
Nicotine and Tobacco
 
Statistical software.pptx
Statistical software.pptxStatistical software.pptx
Statistical software.pptx
 
Cerebellum and control of postures and movements.pptx
Cerebellum and control of postures and movements.pptxCerebellum and control of postures and movements.pptx
Cerebellum and control of postures and movements.pptx
 
Drugs Used in Renal Alteration
Drugs Used in Renal AlterationDrugs Used in Renal Alteration
Drugs Used in Renal Alteration
 
Drugs Used in Endocrine Alteration
Drugs Used in Endocrine AlterationDrugs Used in Endocrine Alteration
Drugs Used in Endocrine Alteration
 
Antidiabetic drugs
Antidiabetic drugsAntidiabetic drugs
Antidiabetic drugs
 
Pancreatic Hormones
Pancreatic HormonesPancreatic Hormones
Pancreatic Hormones
 
Terrestrial laboratory animals
Terrestrial laboratory animalsTerrestrial laboratory animals
Terrestrial laboratory animals
 
Drugs used in haematological disorders
Drugs used in haematological disordersDrugs used in haematological disorders
Drugs used in haematological disorders
 
Laboratory animals
Laboratory animalsLaboratory animals
Laboratory animals
 
Immunomodulators-1.pptx
Immunomodulators-1.pptxImmunomodulators-1.pptx
Immunomodulators-1.pptx
 
Immunomodulators - 3.pptx
Immunomodulators - 3.pptxImmunomodulators - 3.pptx
Immunomodulators - 3.pptx
 
Immunomodulators - 2.pptx
Immunomodulators - 2.pptxImmunomodulators - 2.pptx
Immunomodulators - 2.pptx
 

Recently uploaded

Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxJisc
 
How to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSHow to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSCeline George
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxVishalSingh1417
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxRamakrishna Reddy Bijjam
 
Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsKarakKing
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfSherif Taha
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsTechSoup
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsMebane Rash
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxVishalSingh1417
 
Single or Multiple melodic lines structure
Single or Multiple melodic lines structureSingle or Multiple melodic lines structure
Single or Multiple melodic lines structuredhanjurrannsibayan2
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdfQucHHunhnh
 
Spellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseSpellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseAnaAcapella
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin ClassesCeline George
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - Englishneillewis46
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfagholdier
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the ClassroomPooky Knightsmith
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024Elizabeth Walsh
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentationcamerronhm
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxDenish Jangid
 

Recently uploaded (20)

Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptx
 
How to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSHow to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POS
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdf
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
Single or Multiple melodic lines structure
Single or Multiple melodic lines structureSingle or Multiple melodic lines structure
Single or Multiple melodic lines structure
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
Spellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseSpellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please Practise
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - English
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the Classroom
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 

Anticancer drugs 2 alkylating agents

  • 1. Anticancer Alkylating agents Dr. S. Parasuraman Faculty of Pharmacy, AIMST.
  • 2. Alkylating agents Nitrogen mustards Ethylenimine Alkyl sulfonate Nitrosoureas Triazine Methylhyderazine Mechlorethamine Cyclophosphamide Ifosfamide Chlorambucil Melphalan Thio-TEPA Busulfan Carmustine Lomustine Dacarbazine Temozolomide Procarbazine
  • 3. Alkylating agents • Alkylating agents produce highly reactive carbonium ion intermediates or related transition complex which transfer alkyl group to cellular macromolecules by covalent bonds. • Alkylating agents cross link with carboxyl, hydroxyl, amino, sulfhydryl and phosphate groups of biomacromolecules results abnormal base paring/ scission of DNA Stand.
  • 4. Alkylating agents MOA & SAR: The chemotherapeutic and cytotoxic effects are directly related to the alkylation of DNA. The 7th nitrogen atom of guanine is suitable for formation of covalent bond with bifunctional alkylating agent.
  • 5. Pharmacological actions • Cytotoxic actions: – Interfere with DNA integrity and functions to induce cell death in rapidly proliferating tissues. – Lethality of DNA alkylation depends on the recognition of the adduct, the creation of DNA stand breaks by repair enzymes. – In nondividing cells, DNA damage activation depends on the presence of p53 gene. Malignant cells with mutant/ absent p53 gene fail to suspend cell-cycle progression (don’t cause apoptosis) and exhibit resistance to alkylating agents.
  • 6. Toxicities of alkylating agents • Bone marrow toxicity – Causes dose-dependent toxicity to bone marrow elements – Myelosuppression – Suppression of cellular and humoral immunity • Mucosal toxicity – Highly toxic to mucosal cells and intestinal mucosa • Neurotoxicity – Nausea, vomiting (after I.V administration) – Ifosfamide is the most neurotoxic agent in this class (alter mental status, coma, generalized seizures and cerebellar ataxia) • Other: Leukemogensis, male and female reproductive system toxicity.
  • 7. • Mechlorethamine – – – – – First nitrogen mustard; most reactive Slow I.V. injection may cause sloughing Used for Hodgkin and non-Hodgkin lymphomas Largely replaced by cyclophosphamide and melphalan. Dose: 0.1 mg/kg i.v. daily X 4 days (courses may be repeated at suitable intervals) – It is also used topically for treatment of cutaneous T-cell lymphoma – Toxicity: Block reproductive functions, produce menstrual irregularities or premature ovarian failure in women and oligospermia in men. First trimester of pregnancy and later stage of pregnancy it should not be used.
  • 8. • Cyclophosphosphamide – Inactive as such – Transformed to active metabolites in liver: (aldophosphamide, phosphoramide mustard) – Chloramphenicol retards the metabolism of cyclophosphamide. – It is well absorbed orally, activated by CYP2B. – Cyclophosphamide is potent immunosuppressive agent, it has been used to prevent organ rejection after transplantation. – Dose: 2-3 mg/kg/ day oral; 10-15 mg/kg i.v.
  • 9. • Ifosfamide – Analog of cyclophosphamide has a longer dose-dependent t1/2 and it also activated by hydroxylation in the liver. – Used in bronchogenic, breast, testicular, bladder, head and neck carcinomas, oeseogenic sarcoma and some lymphomas. – Approved for germ cell testicular cancer – Produce dose limiting toxicity – haemorrhagic cystitis. Sever urinary tract and CNS toxicity – Toxicity can be reduced by administering mesna (-SH compound). mesna inactivates the vasicotoxic metabolites of ifosfamide and cyclophosphamide. – Ifosfamide causes less alopecia and is less emetogenic than cyclophosphamide. – Dose: 0.1 g inj.
  • 10. • Chlorambucil – Slow acting alkylating agent – Active against lymphoid, myeloid tissue cancers – It is the drug of choice for the long-term maintenance therapy for chronic lymphatic leukaemia, non-Hodgkin lymphoma and few solid tumours. – It has immunosuppressant property – Dose: 4-10 mg daily for 3-6 weeks, then 2 mg/kg daily for maintenance
  • 11. • Melphalan – The pharmacological and cytotoxic properties of melphalan is similar to mechlorethamine. The drug is not a vesicant – Effective in multiple myeloma and advanced ovarian cancer – Toxicity: Bone marrow toxicity – Dose: 10 mg daily for 7 days or 6 mg/ day for 2-3 weeks-----------4 weeks gap--------- 2 to 4 mg/day for maintenance orally.
  • 12. • Thio-TEPA – – – – It is an ethylenimine Highly toxic Used in ovarian and bladder cancer Dose: 0.3-0.4 mg/kg i.v. at 1-4 weeks intervels
  • 13. • Busulfan – Highly specific for myeloid elements and granulocyte – Toxicity: hyperuricaemia is common; pulmonary fibrosis and skin pigmentation are specific adverse effects. – Drug of choice for chronic myeloid leukaemia – Dose: 2-6 mg/ day, orally
  • 14. • Nitrosoureas – It is lipid soluble alkylating agents with a wide range of antitumour activity. – Cross BBM – Effective in meningeal leukaemias and brain cancer – Toxicity: Nausea, vomiting are common; CNS toxicity, bone marrow depression (delayed effect; will take 6 weeks to develop), visceral fibrosis and renal damage can occur – Dose: 100-130 mg/m2 BSA single oral dose every 6 weeks.
  • 15. • Dacarbazine (DTIC) – After activation in liver, the active metabolite methylate the DNA and interfere with its function. – Used for malignant melanoma, Hodgkin’s disease – Toxicity: Nausea, vomiting, flu-like symptoms, neuropathy and myelosuppression – Dose: 3.5 mg/kg/day i.v. for 10 days, repeated after 4 weeks
  • 16. • Temozolamide – Orally active triazine methylating agent is the drug of choice for glioma and other malignant brain tumour. – Also used for melanoma – Toxicity: Nausea, vomiting, flu-like symptoms, neuropathy and myelosuppression – Dose: 100- 200 mg/day
  • 17. • Procarbazine – It is not classical alkylating agent, but has similar properties. – After metabolizing, procarbazine methylates and depolymerizes DNA and causing chromosomal damage and inhibit nucleic acid synthesis. – Procarbazine is component of MOPP regimen for Hodgkin’s and related lymphomas and alternative drug for brain tumours. – It is a week MAO inhibitor, produce sedation and other CNS effects. – Interact with food, drugs and alcohol. With alcohol, procarbazine causes hot flushing and disulfiram-like reaction. – Toxicity: Vomiting, leucopenia, thrombocytopenia – Dose: 100 mg/m2/ dayfor 14 days in 28 days cycle.

Editor's Notes

  1. MOPP is a combination chemotherapy regimen used to treat Hodgkin's disease. The acronym is derived from the component drugs of the regimen:Mustargen (also known as mechlorethamine, mustine, nitrogen mustard, or MSD)Oncovin (also known as Vincristine or VCR)Procarbazine (also known as Matulane or Natulan) Prednisone (also known as Deltasone or Orasone)